Covista Q1 2027 earnings

CVSA · 2026-10-29 16:16 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue and adjusted EPS growth accelerated in the first quarter of FY2027, and management raised guidance for the full year.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$511.5M+10.7%—Ex. 99.1, income statement
EPS (GAAP)$1.95+16.8%—Ex. 99.1, income statement
EPS (adjusted)$2.19+25.1%—Ex. 99.1, income statement
Adj. EBITDA$540.9M+9.0%—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Chamberlain$192.4M+7.4%37.6%Total students +1.3% YoY
Walden$216.7M+14.1%42.4%Total students +12.8% YoY
Medical and Veterinary$102.5M+10.0%20.0%Total students +3.5% YoY

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses Operating cost and expense $413.5M (+9.7% YoY)
  • One-offs in the quarter Restructuring expense $163k; Strategic advisory costs $6.2M; Debt modification costs $756k
  • Effective tax rate 31.0% (FY27 YTD)
  • Non-GAAP bridge Adds back restructuring, amortization, strategic advisory costs, debt modification costs, and a U.S. tax benefit from foreign-derived income

KPIs

MetricActualPrior quarterPrior yearChange
Total enrollment104,713—97,260+7.6% YoY
Free cash flow$355.2M$393.1M—-9.6% vs prior quarter
Net leverage0.5x0.5x—Stable

Guidance

MetricGuidePrior guideChange
Revenue$2,060M - $2,095M$2,050M - $2,090M+$10M range
Adjusted EPS$9.00 - $9.20$8.90 - $9.15+$0.10 range

What drove it

  • Revenue story Revenue grew 10.7% YoY, driven by double-digit growth in Walden (+14.1%) and Medical and Veterinary (+10.0%), with Chamberlain growing 7.4%.
  • EPS story Adjusted EPS grew 25.1% YoY, supported by revenue growth, operating leverage, and a U.S. tax benefit from foreign-derived income.
  • One-off check Strategic advisory costs increased to $6.2M from $1.7M YoY; restructuring expense decreased to $163k from $310k YoY.

The good

  • Revenue growth accelerated to 10.7% YoY
  • Adjusted EPS grew 25.1% YoY
  • Management raised FY2027 revenue and adjusted EPS guidance

The bad

  • Operating margin (GAAP) declined to 19.2% from 18.5% YoY
  • Free cash flow decreased 9.6% vs the prior quarter

The ugly

  • none

Open questions

  • What is the impact of the CFO's planned retirement on capital allocation or strategy execution?
  • What specific drivers caused the decline in GAAP operating margin despite revenue growth?
Full release

Earnings: CVSA — filed 2026-10-29

Covista Inc. (CVSA) · Form 8-K, Item 2.02 · Filed · SEC filing

Investor Contact:

Jeremy Cohen

Investor.Relations@Covista.com

​

Media Contact:

Nick Lucido

CovistaMedia@Covista.com

Covista Reports First Quarter Fiscal Year 2027 Results; Raises Fiscal Year 2027 Revenue and Adjusted EPS Guidance

Total enrollment up 7.6% YoY

Revenue up 10.7% YoY

Diluted earnings per share $1.95; Adjusted EPS $2.19, growth of 25.1% YoY

Chief Financial Officer Robert Phelan announces planned retirement; will continue to serve until a successor is named

First quarter highlights

Capital allocation

Increased fiscal year 2027 guidance

​

​

CHICAGO – October 29, 2026 – Covista Inc. (NYSE: CVSA), America’s largest healthcare educator, today reported first quarter fiscal year 2027 results (ended Sep. 30, 2026). This quarter, the Company launched

Purpose at Scale, its three-year strategy to train the next generation of healthcare professionals at industry-leading scale.

Purpose at Scale is underpinned by operational excellence, platform extension, employer integration and a technology focus.

“

Purpose at Scale is delivering and all four pillars of the strategy are contributing to our momentum. Total enrollment grew for the 13th consecutive quarter, powering our double-digit revenue growth and continued margin expansion. On that strength, we are raising our fiscal 2027 guidance,” said Steve Beard, Chairman and Chief Executive Officer, Covista. “The demand behind our strategy is durable, and Covista is critical infrastructure for American healthcare. We serve an urgent need in the communities where care matters most, and by doing that well, we are strategically positioned to create lasting value for our shareholders.”

Financial Highlights

Selected financial data for the three months ended Sep. 30, 2026:

​

Business Highlights

Segment Highlights

Chamberlain

​

​

Walden

​

​

Medical and Veterinary

​

​

Fiscal Year 2027 Outlook

Covista raised its revenue guidance for fiscal year 2027 from a range of $2,050 million to $2,090 million, or approximately 5% to 7% growth year-over-year, to a range of $2,060 million to $2,095 million, or approximately 5.5% to 7% growth year-over-year.

Covista also raised its adjusted earnings per share guidance from a range of $8.90 to $9.15, or approximately 8% to 11% growth year-over-year, to a range of $9.00 to $9.20, or approximately 9% to 11.5% growth year-over-year.

Management Update

Chief Financial Officer Robert Phelan has decided to retire from Covista after nearly seven years, as part of a planned transition. He will remain in this role until a successor is named, with no change in responsibilities. He will support the incoming Chief Financial Officer through a transition period. An active search is underway.

Conference Call and Webcast Information

Covista will hold a conference call to discuss its first quarter fiscal year 2027 results today at 4:00 p.m. CT (5:00 p.m. ET).

The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877 (international participants) and stating “Covista earnings call” or by using conference ID:13762351. The call will be simulcast through the Covista investor relations website at: https://investors.covista.com.

Covista will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (U.S.) or +1 201-612-7415 (international), conference ID: 13762351, or visit the Covista investor relations website.

About Covista

Covista (NYSE: CVSA) is America's largest healthcare educator, serving 100,000 students and supported by a community of 400,000 alumni across five accredited institutions. Through personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. Covista is the parent company of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. For more information, visit covista.com and follow us on

LinkedIn,

Instagram and

YouTube.

​

Financial statements

Income Statement

Three Months Ended — Chamberlain (in millions)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Three Months Ended – September 30, – % Change
Revenue192.4179.27.4%
Operating Income26.725.64.4%
Adj. Operating Income26.725.64.4%
Adj. EBITDA37.635.17.1%
Total Students(2)40,35139,8461.3%

Income Statement

Three Months Ended — Walden (in millions)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Three Months Ended – September 30, – % Change
Revenue216.719014.1%
Operating Income63.653.319.5%
Adj. Operating Income6556.116.0%
Adj. EBITDA71.961.916.1%
Total Students(2)58,88152,21612.8%

Income Statement

Three Months Ended — Medical and Veterinary (in millions)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Three Months Ended – September 30, – % Change
Revenue102.593.110.0%
Operating Income22.316.733.0%
Adj. Operating Income22.316.832.7%
Adj. EBITDA27.421.427.9%
Total Students(2)5,4815,2973.5%

Income Statement

Three Months Ended — (in thousands, except per share data)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025
Revenue511,534462,288
Operating cost and expense:
Cost of educational services220,759200,767
Student services and administrative expense192,585175,734
Restructuring expense163310
Total operating cost and expense413,507376,811
Operating income98,02785,477
Interest expense-9,944-11,090
Other income, net1,4162,486
Income from continuing operations before income taxes89,49976,873
Provision for income taxes-18,017-15,811
Income from continuing operations71,48261,062
Discontinued operations:
(Loss) income from discontinued operations before income taxes-5,420747
Benefit from income taxes1,36523
(Loss) income from discontinued operations-4,055770
Net income and comprehensive income67,42761,832
Basic:
Continuing operations2.111.69
Discontinued operations-0.120.02
Total basic earnings per share1.991.71
Diluted:
Continuing operations2.071.65
Discontinued operations-0.120.02
Total diluted earnings per share1.951.67
Weighted-average shares outstanding:
Basic shares33,95136,111
Diluted shares34,57337,057

Income Statement

Three Months Ended — (in thousands)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Three Months Ended – September 30, – Increase/(Decrease) – $$Three Months Ended – September 30, – Increase/(Decrease) – %
Chamberlain:
Operating income26,73025,6081,1224.4%
Adjusted operating income26,73025,6081,1224.4%
Operating margin13.9%14.3%
Adjusted operating margin13.9%14.3%
Walden:
Operating income63,64953,26910,38019.5%
Amortization of acquired intangible assets1,3942,805-1,411
Adjusted operating income65,04356,0748,96916.0%
Operating margin29.4%28.0%
Adjusted operating margin30.0%29.5%
Medical and Veterinary:
Operating income22,25116,7285,52333.0%
Restructuring expense44-44
Adjusted operating income22,25116,7725,47932.7%
Operating margin21.7%18.0%
Adjusted operating margin21.7%18.0%
Covista(1):
Operating income (GAAP)98,02785,47712,55014.7%
Restructuring expense163310-147
Amortization of acquired intangible assets1,3942,805-1,411
Strategic advisory costs6,2311,6844,547
Debt modification costs756756
Adjusted operating income (non-GAAP)106,57190,27616,29518.1%
Operating margin (GAAP)19.2%18.5%
Adjusted operating margin (non-GAAP)20.8%19.5%

Income Statement

Three Months Ended — (in thousands)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Three Months Ended – September 30, – Increase/(Decrease) – $$Three Months Ended – September 30, – Increase/(Decrease) – %
Chamberlain:
Adjusted operating income (GAAP)26,73025,6081,1224.4%
Depreciation6,0945,375719
Amortization of cloud computing implementation assets2,3861,527859
Stock-based compensation2,3722,570-198
Adjusted EBITDA (non-GAAP)37,58235,0802,5027.1%
Adjusted EBITDA margin (non-GAAP)19.5%19.6%
Walden:
Adjusted operating income (GAAP)65,04356,0748,96916.0%
Depreciation1,7841,940-156
Amortization of cloud computing implementation assets2,2531,2041,049
Stock-based compensation2,7822,653129
Adjusted EBITDA (non-GAAP)71,86261,8719,99116.1%
Adjusted EBITDA margin (non-GAAP)33.2%32.6%
Medical and Veterinary:
Adjusted operating income (GAAP)22,25116,7725,47932.7%

Income Statement

Three Months Ended — (in thousands, except per share data)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025
Diluted earnings per share (GAAP)1.951.67
Effect on diluted earnings per share:
Restructuring expense00.01
Amortization of acquired intangible assets0.040.08
Strategic advisory costs0.180.05
Loss on debt extinguishment and debt modification costs0.020.01
U.S. tax benefit due to an increase in foreign-derived income-0.06
Income tax impact on non-GAAP adjustments(1)-0.06-0.03
Loss (income) from discontinued operations0.12-0.02
Adjusted earnings per share (non-GAAP)2.191.75
Diluted shares34,57337,057

Income Statement

Twelve Months Ended — (in thousands)

Twelve Months Ended – September 30, 2026September 30, 2026
Covista:
Net income (GAAP)257,161
Loss from discontinued operations20,634
Interest expense44,289
Other income, net-6,108
Provision for income taxes79,950
Depreciation and amortization73,836
Stock-based compensation41,104
Restructuring expense6,182
Strategic advisory costs23,109
Debt modification costs756
Adjusted EBITDA (non-GAAP)540,913
Total long-term debt principal510,000
Less: Cash and cash equivalents-222,223
Net debt (non-GAAP)287,777
Net leverage (non-GAAP)0.5x

Balance Sheet

September 30, — (in thousands)

September 30, – 2026June 30, – 2026
Current assets:
Cash and cash equivalents222,223406,316
Restricted cash2,3361,438
Accounts and financing receivables, net241,469169,561
Prepaid expenses and other current assets86,54275,126
Total current assets552,570652,441
Noncurrent assets:
Property and equipment, net324,706302,649
Operating lease assets197,511204,364
Intangible assets, net752,860754,254
Goodwill961,262961,262
Other assets, net139,364137,738
Total noncurrent assets2,375,7032,360,267
Total assets2,928,2733,012,708
Current liabilities:
Accounts payable96,383124,763
Accrued payroll and benefits57,72078,669
Accrued liabilities126,21494,364
Deferred revenue365,096259,125
Current operating lease liabilities33,98434,799
Current portion of long-term debt5,1005,100
Total current liabilities684,497596,820
Noncurrent liabilities:
Long-term debt495,131657,750
Long-term operating lease liabilities219,374207,846
Deferred income taxes69,32061,782
Other liabilities38,30842,325
Total noncurrent liabilities822,133969,703
Total liabilities1,506,6301,566,523
Commitments and contingencies
Total shareholders' equity1,421,6431,446,185
Total liabilities and shareholders' equity2,928,2733,012,708

Cash Flow

Three Months Ended — (in thousands)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025
Operating activities:
Net income67,42761,832
Loss (income) from discontinued operations4,055-770
Income from continuing operations71,48261,062
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation8,1818,293
Amortization of operating lease assets7,0187,216
Depreciation10,86210,296
Amortization of acquired intangible assets1,3942,805

Cash Flow

Twelve Months Ended — (in thousands)

Twelve Months Ended – FY26 – Q1Twelve Months Ended – FY26 – Q2Twelve Months Ended – FY26 – Q3Twelve Months Ended – FY26 – Q4Twelve Months Ended – FY27 – Q1
Net cash provided by operating activities-continuing operations (GAAP)374,796427,890406,335470,796454,438
Capital expenditures-55,936-59,880-69,872-77,696-99,265
Free cash flow (non-GAAP)318,860368,010336,463393,100355,173

Cautionary Disclosure Regarding Forward-Looking Statements

Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “project,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors may not contain all of the factors that are important to you. We cannot assure you that we will realize the results, performance or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. All forward-looking statements are based on information available to us as of the date any such statements are made, and Covista assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.

​

A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, although these special items could be material to Covista's results in accordance with GAAP.

###

​

​

Covista Inc.

Consolidated Balance Sheets

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Consolidated Statements of Income

(unaudited)

(in thousands, except per share data)

​

​

​

​

​

Covista Inc.

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

​

​

​

​

​

Covista Inc.

Segment Revenue

(unaudited)

(in thousands)

​

​

Covista Inc.

Non-GAAP Financial Measures and Reconciliations

We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables:

Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreign-derived income, and loss (income) from discontinued operations.

Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreign-derived income, and loss (income) from discontinued operations.

Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, and debt modification costs.

Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, strategic advisory costs, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income.

Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures.

Net debt – Defined as total long-term debt principal less cash and cash equivalents.

Net leverage – Defined as net debt divided by adjusted EBITDA.

A description of special items in our non-GAAP financial measures described above are as follows:

Covista Inc.

Adjusted Operating Income

(unaudited)

(in thousands)

​

(1)

Consolidated results include Home Office activities not allocated to segments.

​

Covista Inc.

Adjusted EBITDA

(unaudited)

(in thousands)

​

(1)

Consolidated results include Home Office activities not allocated to segments.

Covista Inc.

Adjusted Earnings

(unaudited)

(in thousands, except per share data)

​

​

Note: May not sum due to rounding.

​

Covista Inc.

Free Cash Flow

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Net Leverage

(unaudited)

(in thousands)

​

​

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.